- Active
- Ferric pyrophosphate
Format: Phospholipid-Based Powder Release: Immediate / non-modified
Vezicle™ Liposomal Ferric Pyrophosphate is a phospholipid-based ferric pyrophosphate powder for professiona...
Format: Phospholipid-Based Powder Release: Immediate / non-modified
Vezicle™ Liposomal Ferric Pyrophosphate is a phospholipid-based ferric pyrophosphate powder for professiona...
Product code NG-PEL-007
Format: Taste-Masked and Interaction-Protected IR Pellet Release: Taste-masked immediate release
Single-active taste-masked and interaction-protected ir pellet designed for metallic taste and direct conta...
Product code NG-PEL-008
Format: Taste-Masked IR Pellet Release: Taste-masked immediate release
Single-active taste-masked ir pellet designed for strong bitterness and metallic taste with immediate gastr...
Product code NG-MIC-011
Format: Microencapsulated Powder Release: Immediate / non-modified
Single-active microencapsulated powder designed for metallic taste and direct interaction with flavours and...
Product code NG-MIC-012
Format: Microencapsulated Powder Release: Immediate / non-modified
Single-active microencapsulated powder designed for metallic taste, colour impact, dispersibility and matri...
Technical selection guide
Mineral ingredients may introduce metallic or bitter sensory characteristics and can interact directly with other formulation components. This collection presents liposomal, microencapsulated and pellet options for different technical objectives.
Prioritise the actual requirement: taste masking, reduced direct ingredient contact, dispersion, handling or compatibility within a multi-ingredient blend.
The appropriate format depends on dose, dosage form, accompanying actives, moisture exposure and processing. No platform should be assumed to solve every mineral-formulation problem.
Compare mineral form, active loading, carrier or coating system, release behaviour, sensory evidence and the relevant physical specifications.
Taste-masked pellets retain immediate release unless otherwise stated. Microencapsulation and liposomal delivery have separate evidence requirements and should be assessed from their controlled product documents.
Confirm assay, specification, batch conformity, allergen and GMO status, contaminant limits and regulatory suitability for the intended market.
Finished-product compatibility, permitted dose, labelling and claims remain the customer’s responsibility.